With Novartis facing a potential loss of $9 billion through 2026 from patent expirations, the company announced topline results for Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
If you are not happy with the results below please do another search
50 search results for:
And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday.
Integrated medhealth communication, integrated medhealth communication North America and Pulsar Health have joined forces to provide both agility and excellence in global healthcare communications, coupling scientific expertise with intelligent creativity, delivering meaningful solutions that are unique to the bespoke needs of each client, communicating science and driving meaningful conversation.
Jazz Pharmaceuticals plc announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex (cannabidiol) oral solution reported improvements in patients’ seizure and non-seizure outcomes across all age groups.
Pfizer Inc. and its German partner BioNTech SE said on Monday they have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization of their Omicron-adapted COVID-19 vaccine booster for children aged 6 months through 4 years.
Ionis Pharmaceuticals Inc. announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects fewer than 1,000 people across Europe.
Vaccines company Valneva on Monday reported positive 12-month antibody persistence data for its single-shot Chikungunya vaccine candidate.
Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
Mpox is expected to no longer be considered a public health emergency in the United States from Feb. 1, 2023, the U.S. health department said on Friday.
GSK plans to file for approval of Jemperli in endometrial cancer after the checkpoint inhibitor met its primary endpoint in the Phase III RUBY trial, the company announced Friday.